Federal Gov't Said to Claim Mylan (MYL) Overcharged Medicaid Over EpiPen
- Top 10 News for 10/24 - 10/28: AT&T (T), Time Warner Make it Official; Margins Hamper Apple's Q4; Mergers Aplenty
- Wall St. dips as FBI to review more Clinton emails
- FBI to review more emails related to Clinton's private email use
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mylan (Nasdaq: MYL) shares are on watch following news that the Federal government is accusing the company of overcharging the Medicaid program by millions of dollars for its EpiPen product.
The WSJ noted commentary from Acting Administrator Andy Slavitt of the federal Centers for Medicare and Medicaid Services (CMS) in a letter on Wednesday.
Slavitt said Mylan incorrectly classified EpiPen as generic, when it should have been classified as brand name. That allow Mylan to pay a rebate of just 13%, or around $163 million, versus a rebate of 23.1 percent or more than it should've been paying.
Slavitt noted that the CMS has,
on multiple occasions provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified.
Shares of Mylan are flat Thursday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Memorial Production Partners (MEMP) Said to Weigh Options, Including Bankruptcy
- Volatility and Volume movement
- EpiPen Maker Mylan Hit With Class-Action Lawsuit
Create E-mail Alert Related CategoriesLitigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!